Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Harvard Business School
Johnson and Johnson
Merck
Cantor Fitzgerald
Novartis
Queensland Health
Federal Trade Commission
McKinsey

Generated: October 23, 2017

DrugPatentWatch Database Preview

KEPPRA Drug Profile

« Back to Dashboard

Which patents cover Keppra, and when can generic versions of Keppra launch?

Keppra is a drug marketed by Ucb Inc and is included in four NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in KEPPRA is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

Summary for Tradename: KEPPRA

US Patents:1
Applicants:1
NDAs:4
Suppliers / Packagers: see list7
Bulk Api Vendors: see list78
Clinical Trials: see list63
Patent Applications: see list1,925
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KEPPRA at DailyMed

Pharmacology for Tradename: KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
KEPPRA
levetiracetam
SOLUTION;ORAL021505-001Jul 15, 2003AARXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
KEPPRA XR
levetiracetam
TABLET, EXTENDED RELEASE;ORAL022285-001Sep 12, 2008ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-002Nov 30, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Ucb Inc
KEPPRA XR
levetiracetam
TABLET, EXTENDED RELEASE;ORAL022285-002Feb 12, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-004Jan 6, 2006ABRXYesYes► Subscribe► SubscribeY► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-001Nov 30, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Ucb Inc
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION)021872-001Jul 31, 2006APRXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-003Nov 30, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KEPPRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
KEPPRA
levetiracetam
SOLUTION;ORAL021505-001Jul 15, 2003► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION)021872-001Jul 31, 2006► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-002Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-001Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-004Jan 6, 2006► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-002Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-003Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
SOLUTION;ORAL021505-001Jul 15, 2003► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-001Nov 30, 1999► Subscribe► Subscribe
Ucb Inc
KEPPRA
levetiracetam
TABLET;ORAL021035-003Nov 30, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for KEPPRA

Drugname Dosage Strength RLD Submissiondate
levetiracetamExtended-release Tablet500 mg and 750 mgKeppra XL1/7/2011
levetiracetamTablets1000 mgKeppra1/24/2007
levetiracetamExtended-release Tablets1000 mgKeppra XR1/7/2011
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Cerilliant
US Army
Federal Trade Commission
Deloitte
Argus Health
AstraZeneca
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot